Hormones, phytohormones and the liver: uses and risks
- Authors: Uspenskaya Y.B1, Kuznetzova IV1
-
Affiliations:
- ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
- Issue: Vol 16, No 1 (2014)
- Pages: 35-40
- Section: Articles
- URL: https://ogarev-online.ru/2079-5831/article/view/28290
- ID: 28290
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Yu B Uspenskaya
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава Россииканд. мед. наук, вед. науч. сотр. НИО женского здоровья НИЦ
I V Kuznetzova
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
Email: ms_smith@list.ru
д-р мед. наук, проф., глав. науч. сотр. НИО женского здоровья НИЦ
References
- Герок В., Блюм Х.Е. Заболевания печени и желчевыделительной системы. Пер. с нем. Под ред. акад. РАМН В.Т.Ивашкина, проф. А.А.Шептулина. М.: МЕДпресс - информ, 2009.
- Misra Vijay Laxmi, Khashab Mouen, Chalasani Naga. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk. Curr Gastroenterol Rep 2009; 11: 50-5.
- Aithal G.P, Watkins P.B, Andrade R.J et al. Case definition and phenotype standardization in drug - induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15.
- Akiyama T, Ishida J, Nakagawa S et al. Genistein, a specific inhibitor of tyrosine - specific protein kinases. J Biol Chem 1987; 262: 5592-5.
- Andersson K.K, Kappas A. Hormones and liver function. In: Schiff L, Schiff E.R, editors. Diseases of the liver. Philadelphia: J.B Lippincott 1982; p. 167-235.
- Boocock D.J, Faust G.E, Patel K.R et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16 (6): 1246-52.
- Castiella A, Lucena M.I, Zapata E et al. Autoimmune hepatitis induced by drugs. Gut 2009; 58: A198.
- Chan M.Y, Gho W.M, Chen Z.Y et al. Oestrogen receptor alpha is required for biochanin A-induced apolipoprotein A-1 mRNA expression in HepG2 cells. Br J Nutr 2007; 98: 534-9.
- Chao Y, Chan W.K, Wang S.S et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12 (4): 277-81.
- Chilvers C. Oral contraceptives and cancer. Lancet 1994; 344: 1390-4.
- Codes L, Asselah T, Cazals-Hatem D et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. Gut 2007; 56 (3): 390-5.
- Daghfous R, El Aidli S, Rjeibi I et al. Norgestrel (Lutenyl) induced severe acute hepatitis. Gastroenterol Clin Biol 2004; 28: 94-5.
- Deltenre P, Denninger M.H, Hillaire S et al. Factor V Leiden - related Budd-Chiari syndrome. Gut 2001; 48: 264-8.
- Department of Reproductive Health and Research, World Health Organization. Family planning evidence updates. www.who.int/reproductive-health/family_planning/updates.htm 2008.
- Di Costanzo L, Drury J.E, Penning T.M, Christianson D.W. Crystal structure of human liver Δ4-3-ketosteroid 5β - reductase (AKR1D1) and implications for substrate binding and catalysis. J Biol Chem 2008; 283: 16830-9.
- Elouni B, Ben Salem C, Zamy M et al. Cytolytic hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports. Ann Pharmacother 2010; 44 (12): 2035-7.
- El-Serag H. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35 (5): 72-8.
- El-Serag H, Rudolph K. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132 (7): 2557-76.
- Farges O, Ferreira N, Dokmak S. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011; 60 (1): 85-9.
- Farinati N, De Maria N, Maran C et al. Hepatocellular carcinoma in alcoholic cirrhosis: is sex hormone imbalance a pathogenetic factor. Eur J Gastroenterol Hepatol 1995; 7 (2): 145-50.
- Gemer O, Moscovici O, Ben-Horin C.L et al. Oral contraceptives and liver hemangioma: a case - control study. Acta Obstet Gynecol Scand 2004; 83 (12): 1199-201.
- Giannitrapani L, Soresi M, La Spada E et al. Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006; 1089: 228-36.
- Goldfarb S. Sex hormones and hepatic neoplasia. Cancer Res 1976; 36: 2584-8.
- Hayashida K, Shoji I, Deng L et al. 17b - estradiol inhibits the production of infectious particles of hepatitis C virus. Microbiol Immunol 2010; 54 (11): 684-90.
- Hebbar V, Shen G, Hu R et al. Toxicogenomics of resveratrol in rat liver. Life Sci 2005; 76: 2299-314.
- Hecht Y. Hepatic and biliary repercussions of estrogens: dose or duration of treatment effect. Contracept Fertil Sex (Paris) 1991; 19: 403-8.
- Heresbach D, Deugnier Y, Brissot P, Bourel M. Dilatations sinusoïdales et prise de contraceptifs oraux. A propos d'un cas avec revue de la littérature. Ann Gastroenterol Hepatol 1988; 24: 189-91.
- Kapp N, Tilley I.B, Curtis K.M. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review. Contraception 2009; 80: 381-6.
- Kawakami Y, Tsurugasaki W, Nakamura S, Osada K. Comparison of regulative functions between dietary soy isoflavones aglycone and glucoside on lipid metabolism in rats fed cholesterol. J Nutr Biochem 2005; 16: 205-12.
- Kiriwat O, Petyim S. The effects of transdermal contraception on lipid profiles, carbohydrate metabolism and coagulogram in Thaiwomen. Gynecol Endocrinol 2010; 26 (5): 361-5.
- Klejdus B, Mikelová R, Petrlová J et al. Evaluation of isoflavone aglycon and glycoside distribution in soy plants and soybeans by fast column high - performance liquid chromatography coupled with a diode - array detector. J Agric Food Chem 2005; 53: 5848-52.
- Lamon-Fava S. Genistein activates apolipoprotein A-I gene expression in the human hepatoma cell line Hep G2. J Nutr 2000; 130: 2489-92.
- Lang C, Meier Y, Stieger B et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 43 associated with drug - induced liver injury. Pharmacogenet Genomics 2006.
- Langer M, Chiandussi L, Chopra I.J, Martini L. The endocrines and the liver, 1982.
- Lee Y.M, Choi J.S, Kim M.H et al. Effects of dietary genistein on hepatic lipid metabolism and mitochondrial function in mice fed high - fat diets. Nutrition 2006; 22 (9): 956-64.
- Lei H, Lu F, Dong H et al. Genistein reverses free fatty acid - induced insulin resistance in HepG2 hepatocytes through targeting JNK J Huazhong Univ Sci Technolog Med Sci 2011; 31 (2): 185-9.
- Lindgren A, Olsson R. Liver damage from low dose oral contraceptives. J Intern Med 1993; 234: 287-92.
- Mahady G, Fabricant D, Chadwick L, Dietz B. Black Cohosh: An Alternative Therapy for Menopause? Nutr Clin Care 2002; 5 (6): 283-9.
- Maio M Di, Daniele B, Pignata S et al. Is human hepatocellular carcinoma a hormone - responsive tumor? World J Gastroenterol 2008; 14 (11): 1682-9.
- Meier Y, Pauli-Magnus C, Zanger U.M et al. Interindividual variability of canalicular ATP-binding - cassette (ABC)-transporter expression in human liver. Hepatology 2006; 44: 62-74.
- Misra Vijay Laxmi, Khashab Mouen, Chalasani Naga. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk. Curr Gastroenterol Rep 2009; 11: 50-5.
- Nagasue N, Kohno H, Yamanoi A et al. Progesterone receptor in hepatocellular carcinoma: correlation with androgen and estrogen receptors. Cancer 1991; 67 (10): 2501-5.
- Naser B, Schnitker J, Minkin M.J et al. Suspected black cohosh hepatotoxicity: no evidence by meta - analysis of randomized controlled clinicaltrials for isopropanolic black cohosh extract. Menopause. 2011; 18 (4): 366-75.
- National Institutes of Health. Workshop on the safety of black cohosh in clinical studies. Washington, DC: National Center for Complementary and Alternative Medicine. NIH Office of Dietary Supplements 2004.
- Neuberger J.M, Davis M, Williams R. Clinical aspects of oral contraceptive associated liver tumours. In: Davis M, Tredger J.M, Williams R, editors. Drug Reactions and the Liver. London: Pitman Medical 1981; 271-83.
- Osterheld J.R, Cosa K, Sandson N.B. Med-Psych drug - drug interactions update: oral contraceptives. Psychosomatics 2008; 49: 168-75.
- Posadzki P, Watson L.K, Ernst E. Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med 2013; 13 (1): 7-12.
- Ricketts M.L, Moore D.D, Banz W.J et al. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J Nutr Biochem 2005; 16: 321-30.
- Ridker P.M, Miletich J.P, Hennekens C.H et al. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 1997; 277: 1305-7.
- Robinson G.E. Low - dose combined oral contraceptives. Br J Obstet Gynaecol 1994; 101: 1036-41.
- Russell R, Kingsland С. The risks and benefits of the combined oral contraceptive pill. J R Coll Physicians Edinb 2008; 38: 224-7.
- Salas A.L, Montezuma T.D, Faria G.G et al. Genistein modifies liver fibrosis and improves liver function by inducing uPA expression and proteolytic activity in CCl4-treated rats. Pharmacology 2008; 81 (1): 41-9.
- Salas A.L, Ocampo G, Fariña G.G et al. Genistein decreases liver fibrosis and cholestasis induced by prolonged biliary obstruction in the rat. Ann Hepatol 2007; 6 (1): 41-7.
- Schindler A.E, Campagnoli C, Druckmann R et al. Classification and pharmacology of progestins Maturitas 2003; 46 (1): 7-16.
- Setchell K, Brown N, Desai P et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001; 131: 1362-75.
- Shimizu I, Yasuda M, Mizobuchi Y et al. Suppressive effect of oestradiol on chemical hepatocarcinogenesis in rats. Gut 1998; 42 (1): 112-9.
- Spitzer D, Krainz R, Graf A.H et al. Pregnancy after ovarian stimulation and intrauterine insemination in a woman with cavernous macrohemangioma of the liver. A case report. J Reprod Med Dec 1997; 42 (12): 809-12.
- Takahashi Y, Odbayar T.O, Ide T.J. A comparative analysis of genistein and daidzein in affecting lipid metabolism in rat liver. Clin Biochem Nutr 2009; 44 (3): 223-30.
- Uetrecht J. Idiosyncratic drug reactions: past, present,and future. Chem Res Toxicol 2008; 21: 84-92.
- Villaseca P. Non - estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Climacteric 2012; 15 (2): 115-24; doi: 10.3109/13697137.2011.624214. Epub 2011 Dec 8.
- Wong C.K, Keung W.M. Bovine adrenal 3b - hydroxysteroid dehydrogenase (E.C. 1.1.1.145)/5-ene-4-ene isomerase (E.C. 5.3.3.1): characterization and its inhibition by isoflavones. J Steroid Biochem Mol Biol 1999; 71: 191-202.
- Yang W, Lu Y, Xu Y et al. Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor - associated macrophages (TAMs). J Biol Chem 2012; 287 (48): 40140-9.
- Yeh S, Chen P. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 2010; 78 (1): 172-9.
- Yu M.W, Chang H.C, Chang S.C et al. Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B- and C-related risk. Hepatology 2003; 38 (6): 1393-400.
- Zhang H, Cui D, Wang B et al. Pharmacokinetic drug interactions involving 17-alpha - ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 2007; 46: 133-57.
- Zollner G, Fickert P, Silbert D et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003; 38: 717-27.
- Zollner G, Fickert P, Zenz R et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001; 33: 633-46.
Supplementary files
